In metastatic breast and prostate cancer patients, RANKLi have been shown to directly influence both primary and secondary tumorigenesis through NFkB inhibition, leading to decreased tumor growth and lower SRE rates in patients receiving RANKLi compared to those receiving BPs [20]. This evidence concerns the gene NFKB1 and Familial prostate cancer.